Myocardial Recovery Following Left Ventricular Assist Device Therapy by M. Navaratnarajah et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Myocardial Recovery Following  
Left Ventricular Assist Device Therapy 
M. Navaratnarajah, M. Ibrahim, M. Yacoub and C. Terracciano 
Heart Science Centre, Imperial College London, Harefield Hospital 
United Kingdom 
1. Introduction 
Heart Failure (HF) represents an increasing clinical problem with a reported mortality (for 
either diastolic or systolic HF) of approximately 60% at 5 years after diagnosis (Shahar et al. 
2004). The incidence of end-stage HF has increased four-fold in the last 20 years (Hubler et 
al. 2003; Terracciano et al. 2010). Symptomatic HF confers a worse prognosis than the 
majority of cancers, with mortality as high as 45% at one year (Cohn 1996; Jessup and 
Brozena 2003), and there are currently more than 16 million people in Europe and the 
United States (US) suffering from this disease. HF is also a major burden in the developing 
world (Mayosi 2007). Despite substantial medical advances in the treatment of HF, cardiac 
transplantation (CTx) remains the best long term therapy for patients suffering from end-
stage disease, with 50 % survival at 10 years post CTx (Hunt, SA et al. 2009a; Trulock et al. 
2007). A fixed and inadequate donor organ pool means that CTx is available to only a small 
proportion of eligible patients. In the US an estimated 100 000 patients are believed to be 
suitable for CTx (Maybaum et al. 2008), but only 2200 transplants are performed annually 
(Hunt,SA et al. 2009b). As a consequence the use of LVADs as Bridge-to-Transplantation 
(BTT) has increased steadily over the last few years and approximately 9000 CTx candidates, 
i.e. more than a third of all listed candidates in the US, have undergone LVAD implantation 
since 1999 (Mancini and Lietz 2010).  
Initially, LVADs were utilised in the acute setting, in the management of post-cardiotomy 
cardiogenic shock (PCCS), a rare clinical scenario associated with high morbidity and 
mortality (Mehta et al. 1996). Despite improvements in LVAD technology, and the 
understanding of PCCS, the use of mechanical unloading (MU) in this acute setting is now 
minimal, with large studies showing survival of 23-52.4% (Sylvin et al. 2010).  
The role of LVADs subsequently expanded to incorporate patients with severe drug-
resistant HF, primarily as a BTT, with subsequent extension of the role to include 
“destination therapy” (DT) in those patients unsuitable for CTx (Kirklin et al. 2011). 
In a small minority of patients a third application for chronic LVAD therapy, “Bridge-to-
Recovery” (BTR) evolved, following the observation that MU appeared to coincide with 
cellular, molecular, electrophysiological and structural myocardial changes consistent with 
functional recovery (Altemose et al. 1997; Farrar et al. 2002; Heerdt,PM et al. 2000a; Hetzer et 
al. 2000; Ogletree-Hughes et al. 2001; Sylvin et al. 2010; Young 2001). Such observations 
allied with anecdotal examples of cardiac recovery in isolated patients following enforced 
device removal (mandated by the development of complications) (Frazier 1994; Frazier and 
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Myers 1999), alerted the world to the possibility that the remodelling of end-stage HF was 
reversible (“reverse remodelling”) (Klotz et al. 2008).  
Within the context of an increasing incidence of HF, amongst a growing population of older 
patients (> 65 yrs) ineligible to receive CTx, inadequate organ availability and ever 
improving pump technology, the concept of BTR offers great hope as a potential treatment 
strategy to either replace, or work alongside that of CTx in years to come. However, BTR i.e. 
sufficient recovery of cardiac function to allow explantation of device, remains a 
controversial subject, with few successful reported cases worldwide(Birks et al. 2006; Birks 
et al. 2011; Maybaum et al. 2007). The Harefield protocol, a novel strategy in which LVAD is 
combined with pharmacotherapy including the β2-AR agonist Clenbuterol, significantly 
increases the rate of explantation (Birks et al., 2006;Birks et al., 2011; see section 6 of this 
Chapter). In general, explantation rates vary considerably between studies but, with the 
exception of the Harefield protocol, remain universally low within the context of chronic HF 
(Dandel et al. 2005; Simon et al. 2005). 
The purpose of this chapter is to review the effects of LVAD therapy, focussing on the 
mechanisms mediating functional recovery. We review clinical and experimental data 
supporting and opposing the concept of BTR. The first section of this chapter will focus on 
myocardial reverse remodelling followed by the clinical aspects of BTR. 
2. Myocardial reverse remodelling 
Myocardial remodelling associated with LVAD therapy is known to occur at structural, 
whole heart, cellular, molecular, metabolic, electrophysiological, cell survival and functional 
levels. 
2.1 LVAD induced reverse structural remodelling  
2.1.1 Restoration of cardiac geometry and regression of myocyte hypertrophy 
LVAD therapy has been shown to reduce left ventricular dimensions (Frazier et al. 1996) 
and to restore the end-diastolic-pressure volume relationships (EDPVR) towards normal 
values (Levin et al. 1995). In addition, regression of both cardiac and myocyte hypertrophy 
has been consistently demonstrated to occur during LVAD treatment (Madigan et al. 2001; 
Zafeiridis et al. 1998).  
Pharmacotherapy alone has proved effective in retarding the negative remodelling 
associated with HF (Yancy et al. 2001), but is unable to induce profound reverse remodelling 
to the extent of LVAD therapy (Levin et al. 1995). The structural changes described have not 
been documented in the right ventricle (RV) of LVAD supported patients, suggesting that 
the predominant factor driving remodelling to be haemodynamic (Klotz et al. 2008), rather 
than the normalization of neurohumoral and cytokine environment known to occur during 
support (Birks et al. 2001; Delgado, III et al. 1998; Klotz et al. 2009; McCarthy et al. 1995).  
2.1.2 Cytoskeletal proteins  
Sarcomeric and skeletal protein changes have been consistently shown to occur in 
association with MU. De Jonge et al. demonstrated improvements in distorted cytoskeletal 
architecture involving a number of proteins including actin, tropomyosin, troponin T and 
troponin C (De et al. 2002). Reversal of disruption of the amino terminus of dystrophin 
(Vatta et al. 2004), and upregulation of dystrophin gene expression (Mohapatra et al. 2010) 
occur in LVAD supported patients. Work conducted at Harefield hospital demonstrated a 
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specific collection of protein expression alterations that coincided with functional recovery 
and device explantation, involving a variety of proteins such as myosin heavy chain, 
sarcomeric actin, troponin C, troponin T, lamin A/C , spectrin, integrins beta1, beta6, alpha-
tropomyosin, alpha1-actinin, and vinculin (Birks et al. 2005; Latif et al. 2007).  
2.1.3 Extracellular matrix 
The ECM constitutes approximately 3 % of normal myocardium, and is largely made up of 
collagen. Type 1 collagen, type 1: type 3 collagen ratio, collagen cross linking and fibrosis 
have been shown to be elevated in a variety of clinical as well as experimental disease states 
(Avendano et al. 1999; Badenhorst et al. 2003; Marijianowski et al. 1995; Mukherjee and Sen 
1991; Porter and Turner 2009; Woodiwiss et al. 2001).  
Reports of LVAD-induced ECM changes have been conflicting, with some revealing 
increased myocardial fibrosis and ECM volume following unloading (Klotz, S. et al. 2005b; 
Li et al. 2001; Matsumiya et al. 2005; Saito et al. 2010), and others showing a reduction 
(Akgul et al. 2004; Bruckner et al. 2001; Maybaum et al. 2007; Thohan et al. 2005; Thompson 
et al. 2005). Bruggink et al. demonstrated a biphasic response with initial expansion of ECM 
and then a subsequent regression with prolonged MU (Bruggink et al. 2006). This 
discrepancy is thought to arise from differences in HF aetiology, duration of MU, 
pharmacotherapy employed during MU (Klotz,S et al. 2007a), as well as the varying and 
often semi-quantitative methods utilised for analysis (Bruckner et al. 2000).  
Matrix metalloproteinases (MMPs) are a group of enzymes responsible for collagen 
degradation and are tightly regulated by tissue inhibitors of metalloproteinases (TIMPs). HF 
is associated with large changes in MMP and TIMP action and thus ECM composition (Li et 
al. 2001; Matsumiya et al. 2005), and it is understood that altered regulation in their 
expression contributes to “negative” ECM remodelling in HF (Mann and Spinale 1998; 
Spinale et al. 2000; Wilson and Spinale 2001). Normalisation (decrease) of MMP1:TIMP1 
ratio has been reported with LVAD use in a DCM population and coincides with increased 
LV collagen cross linking, type 1: type 3 ratio and increased ventricular stiffness (Klotz,S et 
al. 2005b). A study conducted at Harefield hospital showed that all but one (TIMP4) of the 
MMPs and TIMPs studied, displayed a change in expression during LVAD therapy (Felkin 
et al. 2009). TIMP4 expression decreased in this study in contrast to previous studies 
showing unchanged/decreased MMP and augmented TIMP levels to coincide with LVAD 
support (Klotz,S et al. 2005b; Li et al. 2001). Levels of cardiac fibrosis (Matsumiya et al. 2005; 
Saito et al. 2010) and profibrotic marker gene expression (Felkin et al. 2009) at time of LVAD 
implantation demonstrate predictive power with regards to likelihood of subsequent 
functional recovery, device explantability and durability of recovery. Negative ECM 
remodelling may represent a potentially important modifiable barrier to recovery in HF 
patients (Klotz, S. et al., 2007b).  
Pharmacological blockade of the Renin-Angiotensin-Aldosterone-System (RAAS) in HF 
therapy is known to decrease cardiac fibrosis, collagen content and ventricular dilatation, 
with significant improvements in mortality (Arnold et al. 2003). Similar effects on ECM have 
also been seen in several different experimental models of HF (Bartha et al. 2008; Ibrahim et 
al. 2009; Meng et al. 2009). Klotz et al. have shown that ACE inhibition (ACE-I) reduces the 
increase in LV myocardial Angiotensin II/noradrenaline (NA) (Klotz et al. 2009), total 
collagen levels and collagen crosslinking associated with LVAD therapy, leading to their 
suggestion that pharmacological manipulation of the ECM represents a critical target in 
improving the frequency and extent of recovery during LVAD therapy (Klotz, S. et al. 2007b). 
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No changes in RV chamber size, mass or collagen content were noted despite normalisation 
of MMP:TIMP ratio and myocardial Ang II levels, inferring that neither haemodynamic 
unloading nor pharmacotherapy alone were sufficient for positive structural ECM 
remodelling to occur, and that complex dual regulation (neurohumoral and haemodynamic) 
of fibrotic mechanisms is likely to exist. All patients were bridged to CTx in this 
retrospective study and hence the impact of these structural ECM changes on whole heart 
cardiac functional recovery was not assessed.  
2.2 LVAD effects on Ca
2+
 regulation and signaling pathways  
2.2.1 Ca
2+
 regulation  
HF is associated with alterations in a multitude of Ca2+ regulatory mechanisms, the balance 
of which varies with stage and aetiology of disease (Bers 2006). Mishandling of cytoplasmic 
Ca2+ causes deranged myocyte excitation-contraction (EC) coupling, abnormal systolic and 
diastolic function, as well as arrythmogenesis in clinical and experimental HF (Gwathmey et 
al. 1987; Pieske et al. 1996). LVAD therapy is associated with reversal or alteration in 
expression and function, of many Ca2+ handling elements known to be adversely remodelled 
during HF, with a clear correlation with functional recovery being observed with certain 
parameters. Despite this, the true functional relevance of many of the LVAD- associated 
changes in Ca2+cycling remains unclear.  
Reverse electrophysiological remodelling occurs during LVAD therapy, demonstrated by     
reduction of QT interval and myocyte action potential duration (APD) (Harding et al. 2001). 
Mechanisms regulating APD involve alteration in function and expression of ion 
transporters with changes in depolarising and hyperpolarising currents. Detrimental effects 
of APD prolongation in HF on EC coupling, cellular relaxation and contraction are recognized 
(Gaughan et al. 1999; Wickenden et al. 1998), as well as positive effects such as augmentation 
of intracellular Ca2+ via alteration in L-type Ca2+ and NCX currents, presumed to be 
compensatory adaptive mechanisms (Bouchard et al. 1995; Weber et al. 2002; Wickenden et 
al. 1998). APD reduction has been associated with functional clinical recovery during LVAD 
support (Terracciano et al. 2004), but delineation of a precise contributory role of APD to 
functional recovery is difficult as the specific role of APD changes in HF itself remains unclear. 
2.2.2 Sarcoplasmic reticulum Ca
2+ 
content 
A key determinant of effective Ca2+ release and myocyte contractility is the sarcoplasmic 
reticulum (SR) Ca2+ content and this parameter has been shown to be decreased in HF (Bers 
2006) although increased SR Ca2+ content is noted to occur in some models during 
compensated HF (Soppa et al. 2008). 3 main mechanisms are thought to be responsible for 
the diminished SR Ca2+ content in HF : a) depressed Serca 2a function b) enhanced NCX 
function and c) enhanced SR Ca2+ leak (Bers 2006). Increased SR Ca2+ uptake has been shown 
to occur in response to LVAD support (Dipla et al. 1998; Frazier et al. 1996), and together 
with augmented Ca2+ transient amplitude correlate with improved myocyte contractility 
(Chaudhary et al. 2004; Dipla et al. 1998). Importantly, recovery of diminished SR Ca2+ 
content and L-type fast inactivation (most likely secondary to increased SR Ca2+ release) 
correlated with myocardial recovery and device explantation (Terracciano et al. 2004).  
2.2.3 Serca 2a 
Sarcoplasmic Endoreticulum Ca2+ ATPase 2a (SERCA 2a) is the principal protein responsible 
for the reuptake of Ca2+ into the SR, which allows for sufficient replenishing of Ca2+ stores 
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for the subsequent heartbeat. Effects on Serca 2a gene expression and protein levels vary. 
Clinical and experimental studies have shown recovery (Takaseya et al. 2004), as well as no 
change (Chaudhary et al. 2004) to occur with MU, in addition to a biphasic response, i.e. 
initial recovery followed by subsequent decline coinciding with contractile function 
deterioration (Oriyanhan et al. 2007). Similarly, phospholamban (PLB) PLB:Serca2a ratio a 
key determinant of contractile function (Koss et al. 1997), known to be elevated in HF, 
displays a similar short term recovery (decreased ratio), with later resurgence of ratio 





 exchanger (NCX) 
Enhanced NCX activity / gene expression and protein levels are known to occur in most but 
not all models of HF (Bers 2006) with certain studies showing no change(Hasenfuss et al. 
1999; Komuro et al. 1992) or even a reduction (Heerdt,PM et al. 2000b). In an environment of 
high intracellular Na+, prolonged APD and diminished Ca2+ transients, enhanced NCX 
activity promotes Ca2+ entry, a probable inotropic action. Reported LVAD-induced NCX 
changes are equivocal, improved Ca2+ extrusion has been associated with increased NCX 
gene expression and functional recovery (Terracciano et al. 2007). However, partial 
restoration of positive force frequency relationship (FFR) (Chaudhary et al. 2004), as well as 
enhanced contractile strength in non-recovered patients (Heerdt,PM et al. 2000a), occurs in 
the absence of alterations in NCX protein levels. The well documented discordance between 
gene expression and protein levels, as well as regional LV expression heterogeneity, may be 
responsible for such discrepancies.  
2.2.5 Ryanodine receptor (RyR) 
Diastolic Ca2+ leak secondary to deranged RyR function is also an important contributor in 
Ca2+ mishandling in HF(Marx et al. 2000). Chronic PKA mediated hyperphosphorylation of 
RyR2 promoting a “leaky” receptor is just one of the proposed mechanisms thought to lead 
to SR Ca2+ depletion and disease progression in HF (Kushnir and Marks 2010; Shan et al. 
2010), and normalisation of this parameter has been seen to occur with LVAD support(Marx 
et al. 2000).  
2.2.6 Beta-adrenergic signalling 
Improvement of beta-AR (β-AR) responsiveness and density occurs during LVAD therapy 
(Dipla et al. 1998; Klotz, S. et al. 2005a; Milting et al. 2006; Ogletree-Hughes et al. 2001), as 
well as mechanically unloaded failing rat hearts (Oriyanhan et al. 2007). LVAD induced  
β-AR “recovery” is independent of cessation of systemic β-AR agonist therapy (Ogletree-
Hughes et al. 2001), of greater magnitude than that caused by pharmacotherapy alone 
(Klotz, S. et al. 2005a), and unrelated to duration of support (Ogletree-Hughes et al. 2001). 
Mechanisms promoting such recovery remain unclear and direct haemodynamic unloading 
and/or normalisation of cytokine and neurohumoral environment are likely to be 
important. Support for the the latter as the predominant governing factor is derived from 
results showing LVAD associated β-AR recovery to occur in both RV and LV, despite 
isolated LV haemodynamic unloading (Klotz, S. et al. 2005b). Alteration in the specific 
expression of genes involved in β-AR signalling such as phosphodiesterase 1A, 3B, 
calcineurin A and Rap guanine nucleotide exchange factor 4 RAPGEF4 (EPAC2) has been 
shown to coincide with functional myocardial recovery in patients undergoing device 
explantation (Hall et al. 2007).  
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2.2.7 Neurohumoral effects 
LVAD support is known to decrease plasma adrenaline, noradrenaline (NA), renin, 
aldosterone and vasopressin (Klotz et al. 2009) as well as Atrial and B-type natriuretic 
peptide plasma levels (Thompson et al. 2005), myocardial gene (Kuhn et al. 2004) and 
protein (Wohlschlaeger et al. 2008) expression. Occasional correlation between measured 
biomarkers and functional improvement raises the possibility of the potential use of such 
markers in guiding therapy and prediction of recovery (Thompson et al. 2005). However, 
LVAD effects on the RAAS have recently been shown to be complex, with actual increased 
myocardial Ang II and NA levels, occurring despite reductions in plasma renin and 
aldosterone levels (Klotz et al. 2009). Such changes are postulated to arise from an LVAD 
induced recovery of depleted angiotensinogen levels, leading to enhanced generation of 
myocardial Ang II with subsequent sympathetic stimulation causing elevated NA levels, 
and shown to correlate with increased fibrosis and ventricular stiffness (Klotz et al. 2009), 
structural changes that were prevented by ACE-I. The negative effects of NA and Ang II on 
ECM remodelling and apoptosis are well known (Bonnefont-Rousselot et al. 2002; Klotz, S. 
et al. 2007b), and such findings emphasise the importance of possible pharmacological 
manipulation of specific neuroendocrine pathways in combination with LVADs in 
promoting positive remodelling. 
2.3 Cell survival and regeneration 
2.3.1 Apoptosis 
LVAD therapy appears to have beneficial effects on cell survival and apoptotic pathways 
although results are not uniform amongst studies. There are several distinct apoptotic 
pathways and their regulation is complex. Human HF is generally characterised by loss  
of cardiomyocytes (Narula et al. 2006) but rarely and inconsistently the presence of 
abundant apoptosis is demonstrated (Francis GS 1999).LVAD support causes normalisation 
and augmentation of anti-apoptotic proteins FasExo6Del (Bartling et al. 1999), BCL-XL  
levels (Milting et al. 1999), BCL-2 (Francis et al. 1999), decreased myocardial TNF-α levels 
(Razeghi et al. 2001; Torre-Amione et al. 1999), a cytokine believed to possess apoptotic 
regulatory properties , decreases in markers of DNA fragmentation (Bartling et al. 1999), 
cellular repair (PCNA) (Francis et al. 1999) and markers of cellular apoptosis(Baba et al. 
2000).  
2.3.2 Cardiomyocyte regeneration 
LVAD-induced recovery of pro-apoptotic pathways activated in HF seemingly infers a 
potential for increased cell survival and augmentation of myocyte number, a mechanism 
that easily lends itself to promoting improved cardiac function and recovery. Previously 
held assumptions that cardiomyocytes are terminally differentiated, with severely limited, if 
any, potential to undergo mitotic division have now been challenged (Anversa and Kajstura 
1998). Evidence showing that in response to injury cardiomyocyte division occurs (Beltrami 
et al. 2001; Engel et al. 2006), coupled to work demonstrating the existence of endogenous 
cardiac stem pools (Hosoda et al. 2010; Leri et al. 2005; Urbanek et al. 2005) naturally leads 
to the idea that together with the “anti-apoptotic” effects of LVAD therapy, the favourable 
biochemical and haemodynamic environment afforded by MU may also promote cardiac 
regeneration via increased cardiomyocyte division, or endogenous stem cell proliferation, 
thus reversing HF myocyte loss.  
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Evidence in support of such an LVAD role is limited (Wohlschlaeger et al. 2010). 
Wohlschlaeger et al. recently showed a dramatic 2 fold reduction in mean cardiomyocyte 
DNA and a 2 fold increase in number of diploid cardiomyocytes, together with significant 
decrease in the number of polyploid cardiomyocytes, a characteristic of human cardiac 
hypertrophy (Adler and Sandritter 1980; Sandritter and Adler 1976; Wohlschlaeger et al. 
2010). The authors propose that these findings can be explained by a single unifying theory, 
hypothesising LVAD support to a) ameliorate hypertrophic stimuli that promote the 
transition of “mitotically arrested” cardiomyocytes into the S phase of DNA replication 
(Busk et al. 2002) (reduction in polyploidy), as well as b) promote real cell division or 
progenitor cell proliferation (increase in diploidy and reduction of DNA content per 
cardiomyocyte). Such findings require further mechanistic study, but clearly demonstrate 
the plasticity and reversibility of the cardiomyocyte DNA phenotype in HF, and raise the 
attractive possibility of LVAD-induced cardiac regeneration.   
2.4 Myocardial metabolism and energetics 
Myocardial metabolism and energetics have been shown to be consistently altered in HF 
(Neubauer 2007), resulting in an energy deficient mechanically inefficient heart, 
characterised by diminished ATP and phosphocreatine levels (Ingwall and Weiss 2004; 
Starling et al. 1998). The exact mechanisms remain unclear, but altered carbohydrate 
metabolism and myocardial insulin resistance have been proposed as key determinants of 
deranged energetics in HF and a potential therapeutic target (Ashrafian et al. 2007). LVAD 
therapy has been associated with improved mitochondrial metabolic function (Lee et al. 
1998), and normalisation of mitochondrial cardiolipin constitution in ICM (Heerdt et al. 
2002).. In addition, normalisation of raised myocardial Arginine:glycine amidinotransferase 
(AGAT) mRNA levels, occurs in patients successfully undergoing LVAD explantation as 
part of the Harefield protocol (Hall et al. 2007), reinforcing the importance of altered 
metabolic pathways in HF pathogenesis and future therapy.  
2.5 IGF-1 
Insulin growth factor (IGF-1) has been shown to possess favourable cardiac effects in 
experimental models of HF, with both early and delayed short term IGF-1 administration 
causing cardiac hypertrophy and improvement in function (Duerr et al. 1995; Duerr et al. 
1996). IGF-1 displays anti-apoptotic (Li et al. 1997) as well as regenerative properties in both 
skeletal (Musaro 2005; Pelosi et al. 2007) and cardiac muscle (Santini et al. 2007; Welch et al. 
2002), with cardiac specific IGF-1 expression attenuating disease progression in a mouse 
model of DCM (Welch et al. 2002).  
IGF-1 mRNA levels are elevated at time of explantation of LVAD in patients treated with 
the Harefield protocol, suggesting elevated IGF-1 levels maybe important for the recovery 
process (Barton et al. 2005). 2 clearly defined groups were identified: those in which IGF-1 
mRNA was high at implantation in which it remained high, and those in which IGF-1 
mRNA was low at implantation and increased significantly during recovery. It is highly 
likely that the increase in IGF-1 mRNA seen in this study is induced by the combination 
therapy used in the Harefield protocol, and not MU alone, as previous studies have shown 
no change in IGF-1 expression or IGF pathway activation during isolated LVAD support in 
patients bridged to transplantation (Hall et al. 2004; Razeghi et al. 2003). 
Mechanisms governing the increase in IGF-1 and the subsequent role played in recovery are 
unclear. Findings of positive correlation between IGF-1 levels and MMPs 11, 14, TIMPs 1 
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and 2 as well as stem cell recruitment factor SDF-1 expression, advocate modulation of the 
ECM and cellular regeneration to be important (Barton et al. 2005; Hall et al. 2004). 
Clenbuterol treatment of cultured cardiomyocytes has been shown to increase fibroblast-
derived IGF-1, causing myocyte hypertrophy via paracrine signalling (Bhavsar et al. 2010; 
Hall et al. 2004). This suggests that IGF-mediated prevention of myocardial atrophy may 
also be involved in promoting functional recovery. 
3. Clinical aspects of recovery 
3.1 Pharmacological enhancement of myocardial recovery 
The evidence presented so far suggests that LVAD support can induce significant reverse 
remodelling in end stage HF, but on its own these changes rarely result in clinical recovery. 
However, combined pharmacological and LVAD therapy has been shown to achieve greatly 
improved rates of functional recovery (Birks et al. 2006; Birks et al. 2011) with the greatest 
rates of explantation being achieved using the Harefield protocol.  
3.2 Harefield protocol 
A clinical study at Harefield hospital in 2006 achieved an explantation rate of 73% using a 
novel pharmacological regimen involving the use of the drug clenbuterol, a β2-AR agonist, 
in combination with aggressive high dose conventional medical therapy (lisinopril, 
carvedilol, spironolactone and losartan) (Birks et al. 2006) and pulsatile support. The 
purpose of this novel treatment strategy, was to enhance LVAD induced myocardial 
remodelling with high dose “conventional” pharmacotherapy (Phase 1), and prevent LVAD 
induced myocardial atrophy with high dose (up to 720 mcg tds) clenbuterol (Phase 2). 
Despite the fact this study was a single centred, small, non-randomised study only 
involving a small number of patients (n=15), all with non-ischaemic cardiomyopathy, the 
unprecedented high rates of recovery generated the notion that pharmacological β2-AR 
stimulation may enhance myocardial recovery during LVAD therapy, and that future 
success in making BTR a widespread reality may rest, at least partially upon manipulation 
of this hitherto overlooked pathway. Support for this rationale has been further 
strengthened by recent results showing achievement of a 63.2% explantation rate, amongst a 
DCM cohort (n=20), utilising the same protocol in combination with non-pulsatile 
mechanical support (Birks et al. 2011). 
3.3 Clenbuterol 
Clenbuterol is classified as being a selective β2-AR agent (Baronti et al. 1978) with partial 
agonist activity, displaying a high affinity for both β1-ARs and β2-ARs in a variety of tissues 
(Cohen et al. 1982). β2-AR stimulation by various agonists has been shown to cause skeletal 
muscle hypertrophy in several animal species (Kim et al. 1991). Subsequent results showing 
clenbuterol to possess a direct ”physiological” cardiac hypertrophic effect (Hon et al. 2001) 
prompted its inclusion in Harefield protocol, primarily as an agent to prevent myocardial 
atrophy thought to occur with prolonged MU.  
3.4 Prevention of myocardial atrophy by clenbuterol 
Myocardial atrophy has been widely proposed as one of the mechanisms thwarting 
myocardial recovery during LVAD treatment of HF, and a plausible explanation for low 
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explantation rates. As part of the Harefield protocol, after stable regression of left 
ventricular end diastolic dimensions is confirmed echocardiographically over a 2 week 
period, phase 2 (duration at least 6 mths), consisting of carvedilol being switched to a 
specific β1-AR bisoprolol, and the addition of high dose (titrated up to maximum dose of 720 
mcg tds) clenbuterol, is commenced.  
Lack of echocardiographic measures such as left ventricular posterior wall thickness or relative 
wall thickness (RWT: interventricular septum thickness + posterior wall thickness/LVEDd), 
a known predictor of cardiac stability after explantation (Dandel et al. 2008), coupled with 
the absence of a control group, make it difficult to assess whether “prevention of atrophy” 
actually occurred in this study. Recovery does not seem to correlate with myocyte size, 
suggesting that this is not the most important target promoting BTR (Terracciano et al. 
2004). Evidence regarding an anti-atrophic action of clenbuterol is equivocal, with 
experimental studies both supporting (Soppa et al. 2008) as well as opposing (Tsuneyoshi et 
al. 2005) this effect. A separate small single centre clinical study showed clenbuterol therapy 
(maximum dose 720mcg od) during MU was effective in preventing cellular atrophy, 
despite no echocardiographic change in wall thickness (George et al. 2006).  
3.5 Other clenbuterol effects 
The exact mechanisms through which clenbuterol acts remains unclear, but extensive work 
undertaken over the last decade, has clearly established that beyond the purely 
hypertrophic or “anti-atrophic” effects, originally advocating clenbuterol’s inclusion in the 
Harefield protocol, clenbuterol possesses a wide range of other positive actions. Clenbuterol 
administration for 1 week in normal rats has been shown to cause physiological 
hypertrophy, increased Ca2+ transient amplitude, increased SERCA 2a, PLB, NCX protein 
levels, and increased SR Ca2+ content (Soppa et al. 2005). Clenbuterol (1 week) has also been 
shown to enhance both whole heart and cellular function in chronically failing rodent 
myocardium, either alone or in combination with MU , with normalisation of myofilament 
sensitivity and APD duration and improved NCX activity (Soppa et al. 2008). Increased 
RyR2, SERCA2a protein expression and decreased apoptosis have been demonstrated in a 
similar model of HF after long term (9 weeks) clenbuterol therapy (Xydas et al. 2006). In 
addition, a clear cardioprotective inhibitory G protein dependent anti-apoptotic effect of 
acute clenbuterol administration has been recently shown during ischaemia reperfusion 
(Zhang et al. 2010). Clenbuterol modulation of IGF-1 dependent regenerative and 
hypertrophic pathways, as well as ECM effects may also be responsible for promoting 
functional recovery (Barton et al. 2005; Bhavsar et al. 2010; Hall et al. 2004).  
3.6 Assessment of recovery  
3.6.1 Explantation criteria 
Echocardiographic, heamodynamic and exercise testing criteria form the foundation on 
which explantation decisions are made, but specific assessment methods and criteria vary 
between institutes. At the Berlin Heart Institute LVEF >45%, LVEDd <55mm in the presence 
of normal central pulmonary pressures, during reduced support (Dandel et al. 2008; Muller 
et al. 1997) mandates explantation, whereas Harefield hospital employs the criteria of LVEF 
>45%, LVEDd < 60 mm, LVEDs <50mm, pulmonary capillary wedge pressure <12mm Hg, 
cardiac index >2.8 l min-1 as well as exercise testing criteria, VO2 max of > 16ml kg-1 min-1 
during “off pump” testing (Birks et al. 2011). Dobutamine stress testing has also been 
successfully utilised at the Texas Heart Institute (Frazier and Myers 1999). 
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3.6.2 “Off pump” testing 
Off pump testing protocols have been developed relatively recently, and effectively involve 
cessation of pump flow (> 15 minutes) after systemic heparinisation, followed by assessment 
of heamodynamic and echocardiographic parameters at rest and after exercise. Turning off 
of pulsatile devices is acceptable, however turning off non-pulsatile devices leads to 
retrograde flow across the aortic valve, making functional assessment extremely difficult. 
This is avoided during testing by decreasing pump speed to 6000 RPM, resulting in zero 
forward or back flow, effectively ceasing haemodynamic support, or turning the pump 
“off”. Such “off pump” testing has been shown to be safe and well tolerated in both types of 
device (Birks et al. 2011). 
3.6.3 Predictors of recovery 
Identification of factors favouring recovery has historically been extremely difficult. 
Molecular, histological and biochemical markers associated with functional improvement 
and with recovery have been identified (discussed earlier), but to date no recognised marker 
is featured in weaning criteria, which remains largely determined by echocardiographic and 
haemodynamic parameters. Short duration of HF has commonly but not always been shown 
to favour recovery (Birks et al. 2011), however, recovery of patients with long durations of 
HF has also been achieved. Echocardiographic parameters at time of LVAD implant are not 
predictive of recovery, although sustained improvement, as opposed to progressive 
deterioration in EF, fractional shortening and LV dimensions during LVAD therapy is 
associated with greater likelihood of explantation (Birks et al. 2011).  
3.6.4 Durability of myocardial recovery 
The potential therapeutic value of identifying predictors of relapse in preventing LVAD re-
implantation has attracted huge interest. Dandel et al. identified support duration >6 
months, LVEF <45% and LVEDd >55mm at final pre explant echo, as well as a >10% 
worsening of either of these parameters compared to best obtained value, to be highly 
predictive of early relapse (Dandel et al. 2008). These findings support the idea that 
prolonged MU beyond the “optimal point” results in redilatation and functional 
deterioration (Maybaum et al. 2007). In addition, > 10% decrease in relative wall thickness 
(RWT: interventricular septum thickness + posterior wall thickness/LVEDd), RWT of <0.38 
and duration of HF >5 years, also displayed positive predictive power for post LVAD 
cardiac instability. Post weaning deterioration in EF and LVEDd within the first 6 months 
increases risk of HF recurrence, highlighting the importance of early, regular functional 
surveillance of recovered patients.  
3.6.5 Factors opposing recovery 
It is proposed that as well as positive remodelling LVADs can induce negative remodelling. 
Negative remodelling of the ECM, and myocardial atrophy associated with prolonged MU 
are two potential barriers, thought to be opposing BTR, and pharmacological targeting of 
these components has yielded some clinical success. Regular and precise functional cardiac 
assessment during LVAD therapy is essential in promoting BTR. The increasing proportion 
of new generation devices being implanted as a a means of DT in the US (Kirklin et al. 2011), 
in which functional recovery is neither expected, promoted, nor assessed may represent a 
significant new barrier to BTR. Consequently the fraction of LVADs being implanted in the 
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US as a means of BTR is decreasing (Kirklin et al. 2011) , and a lack of belief in, as well as 
desire to pursue BTR may mean potentially “recoverable” patients will not be optimised or 
even assessed for device explantation in the future.  
4. Conclusions  
Constantly improving technology, the advent of even smaller pumps allowing less 
traumatic implantation and explantation with fewer complications has already, and will 
continue to improve LVAD associated morbidity, mortality and quality of life (Rogers et al. 
2010). Further use of this unique research vehicle to better understand the reversible 
mechanisms involved in HF pathogenesis, will identify new therapeutic targets amenable to 
manipulation. It is probable that if BTR is pursued in future years, recent success suggests it 
should be (Birks et al. 2006; Birks et al. 2011), combination therapy i.e. LVAD + 
pharmacotherapy (existing or novel), gene or stem cell therapy, and even a combination of 
these will yield enhanced rates of recovery. Desires to implant smaller devices in patients 
with less advanced disease, and implement novel partial unloading, or intermittent 
ventricular reloading strategies may further improve the BTR strategy and the results of 
such studies are eagerly awaited.  
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